Participated · Series B · Aug 2024

Human Longevity develops longevity-focused technologies and services centered on an artificial intelligence health risk and recommendation platform. It operates a 100+ Longevity Care membership program designed to identify early stages of major age-related diseases and to increase healthspan and lifespan via its clinical care team and data platform. The program leverages precision-medicine inputs including whole-genome sequencing, whole-body and brain MRI, comprehensive cardiac evaluations, body composition analysis, advanced blood biomarkers, and wearables. By continually adding and analyzing client health data, the company aims to shift care from reactive to proactive, preventative, and personalized. The company plans to invest in additional longevity technologies, services, and new expansion sites globally. Human Longevity is headquartered in San Francisco, CA. Human Longevity operates the Health Nucleus intelligence platform, which combines specialized imaging, whole genome sequencing and other lab tests with machine learning and AI to generate precision health analytics. The company provides in-depth Health Nucleus assessments in La Jolla, CA, delivering risk analyses for cardiac, cancer, metabolic and cognitive issues. Core inputs to the platform include whole genome sequencing, brain and body MRI, cardiac CT (CAT) scans, metabolic tests and additional diagnostics. Human Longevity positions these integrated metrics as a comprehensive standard for measuring health and performance for physicians and patients. The company announced a $30 million financing to support its operations. Proceeds from the financing will be used to enhance the Health Nucleus intelligence platform. Human Longevity, Inc. (HLI) is a San Diego, CA–based genomics company led by co-founder and CEO J. Craig Venter, Ph.D., that aggregates whole-genome, phenotype and clinical data. Its core offerings include the HLI Health Nucleus, a genomic-enhanced clinical research center that combines whole genome sequencing, advanced clinical imaging and machine learning. The company is developing large-scale computing and machine-learning approaches to discover novel insights in medicine. HLI operates the HLI Knowledgebase, which currently contains more than 20,000 complete genomes coupled with phenotype data. Its business also includes a Comprehensive Cancer Program and other sequencing programs. HLI plans to use new funding to grow and expand these products and continue development of the Knowledgebase.

Participated · Seed · Jan 2024

Heranova Lifesciences is a Burlington, Massachusetts–based biotech solely focused on women’s health. Led by CEO Dr. Jonathan Y. Zhao and Chief Diagnostic Medical Officer Dr. Farideh Bischoff, the company develops internally built and externally partnered diagnostics, drugs, and devices. It intends to launch a series of non-invasive endometriosis tests and advance two therapeutic programs: a non-hormonal treatment for endometriosis and a non-antibiotic program for bacterial vaginosis. The company has established presences in the United States and Asia. Heranova aims to address unmet needs in women’s healthcare through integrated diagnostics and therapeutic offerings and has raised capital to support those initiatives.

Participated · Series A · Sep 2020

Sun Genomics is a San Diego-based direct-to-consumer custom probiotics and gut health company founded in 2016 and led by CEO and founder Sunny Jain. Its flagship product, Floré, combines a microbiome test and personalized probiotic formulation using whole-genome sequencing to tailor products to individual gut profiles. The company expanded its line with Floré Defense in July 2020, an all-natural formula aimed at immunity and respiratory health. Sun Genomics intends to use new funding to grow in the custom probiotics market, scale delivery across the U.S., enter international markets, and propel publication of studies with academic institutions. The company also announced the addition of Dr. Jack Gilbert as medical and scientific advisor and Mayank Goel as vice president of growth to support research and commercialization efforts. Sun Genomics' core product, Floré, is a personalized probiotic service that uses DNA sequencing and micro-manufacturing to produce a customer-specific 90-day supply of probiotics. Customers send a micro-stool sample via a kit, receive a full microbiome (DigestiveDNA) analysis, and are shipped a tailored formula. The end-to-end process takes six weeks and costs $300 per 90-day supply; the company says a partnership with Illumina will enable delivery in two weeks by late 2020. Floré is available now on the company website, and Sun Genomics is in discussions with national retailers to expand distribution in 2020. The company highlighted industry awards (NEXTY Best Digestive Health Product and Food Funded Most Innovative Product) and user testimonials as part of its market positioning, and in 2019 closed seed funding to accelerate reach.